72996-78-2

Usage

Chemical Properties

Low Melting Brown Solid

Uses

Intermediate in the preparation of Fentanyl analogues

InChI:InChI=1/C16H22N2O3/c1-3-14(19)12-6-4-5-7-13(12)18-16(15(20)21-2)8-10-17-11-9-16/h4-7,17-18H,3,8-11H2,1-2H3

Upstream product

• 130819-94-2 1-benzyl-4-(propionanilido)piperidine-4-carbonitrile 
• 61085-73-2 Methyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-(phenylmethyl)-4-piperidinecarboxylate oxalate 
• 1159835-31-0 1-(tert-butoxycarbonyl)-4-(phenylamino)piperidine-4-carboxylic acid 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 62-53-3 aniline 
• 1159835-40-1 1-tert-butyl 4-methyl 4-(N-phenylpropionamido)piperidine-1,4-dicarboxylate 
• 85098-64-2 1-benzyl-4-(phenylamino)piperidine-4-carboxylic acid 
• 1096-03-3 1-benzyl-4-phenylaminopiperidine-4-carboxylic acid amide 
• 968-86-5 1-benzyl-4-(phenylamino)piperidine-4-carbonitrile 
• 61085-60-7 methyl 4-(phenylamino)-1-(phenylmethyl)-4-piperidinecarboxylate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 61085-72-1 methyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-benzyl-4-piperidinecarboxylate 

Downstream Products

• 131727-05-4 N-(phenyl)-N-[1-(2-(1H-pyrrol-1-yl)ethyl)-4-methoxycarbonyl-4-piperidinyl]propanamide 
• 131727-66-7 N-(phenyl)-N-[1-(2-oxo-2-(2-thienyl)ethyl)-4-methoxycarbonyl-4-piperidinyl]propanamide 
• 131727-89-4 N-(phenyl)-N-[1-(2-(2,3,4,5-tetrahydro-2-oxo-oxazol-3-yl)ethyl)-4methoxycarbonyl-4-piperidinyl]-propanamide 
• 131728-67-1 1-(1H-Benzoimidazol-2-ylmethyl)-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 
• 131728-43-3 N-(phenyl)-N-[1-(1H-indol-3-yl(methyl))-4-methoxy-carbonyl-4-piperidinyl]propanamide 
• 131728-61-5 OHM 3597 
• 131728-77-3 N-(phenyl)-N-[1-(2-(2,3-dihydro-2-oxo-benzoxazol-3-yl)ethyl)-4-methoxycarbonyl-4-piperidinyl]-propanamide 
• 131728-87-5 N-(phenyl)-N-[1-(7-methoxy-2-oxo-2H-benzopyran-4-yl(methyl))-4-methoxycarbonyl-4-piperidinyl]-propanamide 
• 131729-18-5 1-[2-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-ethyl]-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 
• 131729-08-3 1-[2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-yl)-ethyl]-4-(phenyl-propionyl-amino)-piperidine-4-carboxylic acid methyl ester 
• 131728-89-7 N-(phenyl)-N-[1-(1,4-benzodioxan-2-yl(methyl))-4-methoxycarbonyl-4-piperidinyl]propanamide 
• 69049-29-2 1-[2-(4-benzyl-5-oxo-4,5-dihydro-tetrazol-1-yl)-ethyl]-4-(N-propionyl-anilino)-piperidine-4-carboxylic acid methyl ester 
• 131728-81-9 N-(phenyl)-N-[1-(2-(5-chloro-2,3-dihydro-2-oxo-benzoxazol-3-yl)-ethyl)-4-methoxycarbonyl-4-piperidinyl]-propanamide 
• 131728-23-9 N-(phenyl)-N-[1-(2-(2,6-dioxo-3-ethyl-3-phenylpiperidin-1-yl)ethyl)-4-methoxycarbonyl-4-piperidinyl]propanamide 

Relevant academic research and scientific papers

FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING

This disclosure describes fentanyl haptens, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten-carrier conjugate including, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl, fentanyl derivatives, and fentanyl analogs. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.

New method for synthesizing carfentanil

The invention belongs to the field of synthesis of organic matters and specifically relates to a method for synthesizing carfentanil. The synthesis method comprises the following steps of taking N-Bocprotective group piperidone as a raw material, and carrying out five steps of performing a Bargellini reaction, N-acylation, methylation, deprotection and N-alkylation to obtain a target product, namely the carfentanil. According to the invention, by adopting the new method for synthesizing the carfentanil, the use of a extremely-toxic substance, namely potassium cyanide, is avoided, so that theenvironment-friendly effect is achieved; the yield is high; a synthesis route is relatively simple; and the requirements of a modern high-efficiency and low-cost synthesis idea can be met.

Alternate Process for Remifentanil Preparation

An alternate process for synthesizing opiate or opioid analgesics and anesthetics, and intermediates thereof is provided. In particular, a process of synthesizing synthetic opiate or opioid compounds such as, for example, remifentanil, carfentanil, sufentanil, fentanyl, and alfentanil are disclosed.

A facile method for preparation of [2H3]-sufentanil and its metabolites

An improved process for the synthesis of sufentanil with an overall yield of 26% is described. The reactive and high yielding N-debenzylation of the piperidine intermediate 7 using a mixture of Pd/C and Pd(OH)2 was applied to other drug intermediates affording free amines in short reaction times. The deuterium-labeled sufentanil and the metabolite desmethylsufentanil were synthesized applying the optimized process.

Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as μ-opioid receptor imaging agents

The synthesis, evaluation, and molecular modeling of a series of 18F-labeled 4-anilidopiperidines with high affinities for the μ-opioid receptor (μ-OR) are reported. On the basis of the high brain uptake and selective retention in brain regions that contain a high concentration of the μ-OR, combined with a good metabolic stability, [ 18F]fluoro-pentyl carfentanil ([18F]4) and 2-(±)[18F]-fluoropropyl-sufentanil ([18F]6) were selected as the lead compounds for further evaluation. The binding affinity to the human μ-OR was 0.74 and 0.13 nM for [18F]4 and [ 18F]6, respectively. In vitro autoradiography of [18F] 4 and [18F] 6 on rat brain sections produced patterns in accordance with the known distribution of μ-OR expression. Structure-activity relationships of the fluorinated compounds are discussed with respect to the interaction with an activated-state model of the μ-OR. Taken together, the in vivo and in vitro data indicate that [18F] 4 and [18F] 6 hold promise for studying the μ-opioid receptor in humans by means of positron emission tomography.